These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28959324)

  • 21. Formation of transition metal-doxorubicin complexes inside liposomes.
    Abraham SA; Edwards K; Karlsson G; MacIntosh S; Mayer LD; McKenzie C; Bally MB
    Biochim Biophys Acta; 2002 Sep; 1565(1):41-54. PubMed ID: 12225851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
    Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide.
    Gilchrist IC
    Clin Pharmacokinet; 2003; 42(8):703-20. PubMed ID: 12846593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis.
    Rukshin V; Shah PK; Cercek B; Finkelstein A; Tsang V; Kaul S
    Circulation; 2002 Apr; 105(16):1970-5. PubMed ID: 11997285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of eptifibatide in patients undergoing percutaneous coronary intervention.
    Zeymer U
    Expert Opin Pharmacother; 2007 Jun; 8(8):1147-54. PubMed ID: 17516878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system.
    Gupta AS; Huang G; Lestini BJ; Sagnella S; Kottke-Marchant K; Marchant RE
    Thromb Haemost; 2005 Jan; 93(1):106-14. PubMed ID: 15630499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
    Kleiman NS
    Am J Cardiol; 1997 Aug; 80(4A):29B-33B. PubMed ID: 9291243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physicochemical properties of extruded and non-extruded liposomes containing the hydrophobic drug dexamethasone.
    Bhardwaj U; Burgess DJ
    Int J Pharm; 2010 Mar; 388(1-2):181-9. PubMed ID: 20079409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
    Plosker GL; Ibbotson T
    Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ
    Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel effect of cyclicization of the Arg-Gly-Asp-containing peptide on vitronectin binding to platelets.
    Mohri H; Hashimoto Y; Ohba M; Kumagai H; Ohkubo T
    Am J Hematol; 1991 May; 37(1):14-9. PubMed ID: 1708943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery.
    Maestrelli F; González-Rodríguez ML; Rabasco AM; Mura P
    Int J Pharm; 2006 Apr; 312(1-2):53-60. PubMed ID: 16469460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eptifibatide: a cyclic peptide that selectively inhibits platelet glycoprotein IIb/IIIa.
    Heras M; Escolar G
    Drugs Today (Barc); 2000 May; 36(5):295-311. PubMed ID: 12861353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics.
    Deniz A; Sade A; Severcan F; Keskin D; Tezcaner A; Banerjee S
    Biosci Rep; 2010 Jun; 30(5):365-73. PubMed ID: 19900165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
    PRICE Investigators
    Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
    Granada JF; Kleiman NS
    Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcein release behavior from liposomal bilayer; influence of physicochemical/mechanical/structural properties of lipids.
    Maherani B; Arab-Tehrany E; Kheirolomoom A; Geny D; Linder M
    Biochimie; 2013 Nov; 95(11):2018-33. PubMed ID: 23871914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Entrapment of nucleic acids in liposomes.
    Monnard PA; Oberholzer T; Luisi P
    Biochim Biophys Acta; 1997 Oct; 1329(1):39-50. PubMed ID: 9370243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of thermosensitive liposomal formulations on loading and release of high molecular weight biomolecules.
    Huang X; Li M; Bruni R; Messa P; Cellesi F
    Int J Pharm; 2017 May; 524(1-2):279-289. PubMed ID: 28377318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.
    Deibele AJ; Jennings LK; Tcheng JE; Neva C; Earhart AD; Gibson CM
    Circulation; 2010 Feb; 121(6):784-91. PubMed ID: 20124127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.